Economic and budgetary impact evaluation of isavuconazole (Cresemba^®) versus voriconazole (Vfend^®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system

• Gisele Lemes Veiga Araujo ,

  Roles Conceptualization, Formal analysis, Writing – original draft

  * E-mail: araujo.glv@gmail.com (GLVA); laura.murta@originhealth.com.br (LMA); viponzio@gmail.com (VP); jaime.rocha@pucpr.br (JLR)

  Affiliation Knight Therapeutics, São Paulo, Brazil

  ⨯
• Laura Murta Amaral ,

  Roles Validation, Writing – review & editing

  * E-mail: araujo.glv@gmail.com (GLVA); laura.murta@originhealth.com.br (LMA); viponzio@gmail.com (VP); jaime.rocha@pucpr.br (JLR)

  Affiliation ORIGIN Health, São Paulo, Brazil

  https://orcid.org/0000-0002-0463-505X

  ⨯
• Vinicius Ponzio ,

  Roles Writing – review & editing

  * E-mail: araujo.glv@gmail.com (GLVA); laura.murta@originhealth.com.br (LMA); viponzio@gmail.com (VP); jaime.rocha@pucpr.br (JLR)

  Affiliation Federal University of São Paulo, UNIFESP, São Paulo, Brazil

  https://orcid.org/0000-0003-2991-3084

  ⨯
• Jaime Luis Rocha

  Roles Writing – review & editing

  * E-mail: araujo.glv@gmail.com (GLVA); laura.murta@originhealth.com.br (LMA); viponzio@gmail.com (VP); jaime.rocha@pucpr.br (JLR)

  Affiliation Faculty of Medicine of the Pontifical Catholic University of Paraná, PUC, Paraná, Brazil

  ⨯